![Pharmaceuticals | Free Full-Text | Tumor-Targeted Fluorescent Proteinoid Nanocapsules Encapsulating Synergistic Drugs for Personalized Cancer Therapy Pharmaceuticals | Free Full-Text | Tumor-Targeted Fluorescent Proteinoid Nanocapsules Encapsulating Synergistic Drugs for Personalized Cancer Therapy](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-14-00648/article_deploy/html/images/pharmaceuticals-14-00648-g006.png)
Pharmaceuticals | Free Full-Text | Tumor-Targeted Fluorescent Proteinoid Nanocapsules Encapsulating Synergistic Drugs for Personalized Cancer Therapy
PLOS ONE: The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
![Israel in Panama on Twitter: "Con el tema "Innovation and Entrepreneurship in the Health Care System" el Dr. Salomon Stemmer, Jefe de Investigación e Innovación en el Instituto de Oncología del Centro Israel in Panama on Twitter: "Con el tema "Innovation and Entrepreneurship in the Health Care System" el Dr. Salomon Stemmer, Jefe de Investigación e Innovación en el Instituto de Oncología del Centro](https://pbs.twimg.com/media/E4vetMNXIAIKl8u.jpg)
Israel in Panama on Twitter: "Con el tema "Innovation and Entrepreneurship in the Health Care System" el Dr. Salomon Stemmer, Jefe de Investigación e Innovación en el Instituto de Oncología del Centro
![Frontiers | Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System | Pharmacology Frontiers | Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System | Pharmacology](https://www.frontiersin.org/files/Articles/754390/fphar-12-754390-HTML/image_m/fphar-12-754390-g001.jpg)
Frontiers | Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System | Pharmacology
The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
![Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry | npj Breast Cancer Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-017-0034-6/MediaObjects/41523_2017_34_Fig1_HTML.jpg)